Objective: To evaluate the feasibility, efficacy, and safety of a fully biodegradable poly lactic acid (PLA)-based occluder for atrial septal defect (ASD) closure in an animal model.
| INTRODUCTION
Since first reported by King et al, 1 minimally invasive transcatheter device closure of atrial septal defect (ASD) has gained traction as an alternative to surgery for treatment of this common form of congenital heart disease. However, nickel-titanium-alloy-based traditional devices are xenobiotic and unable to expand with patient's growth resulting in short-and long-term complications such as impaired cardiac compliance, metal allergy, inflammation, pericardial effusion, thrombus formation, cardiac erosion or perforation and atrioventricular block. [2] [3] [4] [5] [6] [7] Aiming at improving safety of transcatheter ASD closure, the BioSTAR biodegradable ASD occluder was introduced in 2003 8 however, incomplete metal scaffold degradation, suitability restricted to smaller defects, residual shunts, 9, 10 and reported complications 11 limited its effectiveness. The present study therefore evaluated feasibility and long-term efficacy and safety of a novel poly lactic acid (PLA)-based ASD occluder for percutaneous ASD closure.
2 | METHODS
| ASD occluder and delivery system
The device was co-designed by Fuwai Hospital and Shanghai Shape Memory Alloy Co. Ltd. The ASD occluder is consisted of two isomers of PLA, that is, poly (L-lactic acid) (PLLA) and poly (D, L-lactic acid) (PDLLA), which have potential to achieve complete degradation. The device entails a PLLA skeleton, PLLA locking tube, and two discs made of PDLLA fabrics. The delivery system includes a pushing tube (external) and pushing wire rope (internal). The occluder is lantern-like;
however, it can be converted to tube-like during delivery or umbrellalike upon final locking by fixing the pushing wire rope while pulling or pushing the pushing tube ( Figure 1 ).
The occluder and delivery system have the following features: the distal ends of the locking tube and skeleton are welded; the proximal end of the locking tube has threads on its internal surface linking it to the pushing wire rope, while the proximal end of the skeleton has threads on its external surface to link it with the pushing tube. In addition, there is a locking mechanism at the proximal end of the locking tube, which in conjunction with the locking groove at the proximal end of the skeleton locks the occluder ( Figure 1 ).
As an innovation, the two discs of the device are linked by the pentagonal skeleton in lieu of the traditional "waist." Although the latter feature might be a limitation in very large ASD closure, it is more desirable for ASDs with narrow paths for devices to get through but 
| ASD model generation
The procedures were performed in a sterilized room with a stable environment (temperature, 25°C; humidity, 50-55%). General anesthesia was induced by intramuscular injection of ketamine (10 mg/kg) and diazepam (0.5 mg/kg) before tracheal intubation and maintained with the same medications. Heparin (300 U/kg) was administered intravenously. Electrocardiogram (ECG), heart rate, blood pressure, oxygen saturation, and end-tidal CO 2 were monitored during the procedure. The animals were placed in a supine position and the right groin was exposed. A short 8F sheath was percutaneously placed into the right femoral vein for procedure performance. 12 ASD was generated at the fossa ovalis by trans-septal needle puncture and dilatation to 4-5 atm pressure of a 12 mm Supercross Balloon (Lepu Medical Technology, Beijing, China). The procedure and ASD diameter measurement were conducted under ultrasound guidance.
| Biodegradable ASD closure device implantation
We chose occluder size according to ASD diameter measured by intraoperative echocardiography. The devices were sterilized by ekibon before use. A 6-Fr multipurpose catheter was introduced through the right femoral vein sheath into the right atrium to catheterize the ASD.
The occluder loaded into the catheter was connected to the delivery system, and then pushed through the delivery sheath into the left atrium under ultrasound guidance. The left-side disc was expanded on the left side of the atrial septum in the left atrial cavity. After ensuring that the left-side disc had clung to the atrial septum, the sheath was withdrawn to deploy the right-side disc on the right side of the atrial septum.
Echocardiography then was used to confirm the location of the occluder in the atrial septum and identify any residual shunting. After checking that both discs were well unfolded and located, the occluder was released by rotating the delivery cable counterclockwise. The sheath and the delivery system were withdrawn, and pressure dressing was applied to the puncture site with necessary hemostasis.
| Postoperative management
Extubation was performed after respiratory recovery. Postoperative antibiotics (penicillin) were used for 7 days to prevent infection. Aspirin (5 mg/kg/d) was administered orally from the second postoperative day to death. The feeding environment temperature ranged from 18°C to 35°C, and humidity from 30% to 60%.
| Follow-up studies
Follow-up of animals after implantation were done to evaluate the short-and long-term complications including but not limited to those were reported in nickel-titanium-alloy-based traditional devices. The contents included daily monitoring of appetite, mental status, physical condition, daily routine, bowel movements, urination, and neurological manifestations (especially dystrophy and hemiplegia); and assessment by TTE, ECG, and blood testing, which besides preoperatively was conducted for every three animals at 1, 3, 6, 12, 18, and 24 months after implantation, respectively, after which they were sacrificed and their hearts removed. Baseline and follow-up assessment was geared at evaluating the effectiveness and safety of the occluders by documenting nutritional status, inflammatory status, coagulation function, thrombosis, occluder location and shape, and cardiac structure and function.
Occluder location and shape and adjacent anatomic structures were evaluated by gross anatomical examination. Hematoxylin-eosin (H&E) staining and electron microscopy were used to assess the hyperplasia of tissues surrounding occluders and PLLA degradation.
The PLLA skeletons were separated from the tissues, dried, and weighed at every point to determine the molecular weight loss during degradation. Mass-average molecular weight (Mw) of initial frameworks and partially degraded residues were determined using a VE2001 GPC Max system (Viscotek, Malvern Instruments, Worcestershire, UK). 
| Anatomical pathology
In gross anatomical examination, occluders were in the interatrial septum after procedure, away from the mitral valve, tricuspid valve, superior and inferior vena cava, and right superior and inferior pulmonary veins. During follow-up, there were no vegetations or thrombus formation on occluder surfaces, and the tissue covering the surfaces of both discs gradually thickened, that is, endothelialization (described detailly in following section). The left atrial side of the device showed slower fusion with surrounding tissue than the right atrial side, that is, the left atrial side axis was slightly longer than the right one, and the marginal tissue covering the disc was thicker at the edge than at the center. H&E staining showed no severe inflammation, thrombus, or infarction was apparent during follow-up.
The specimens of other organs (liver, spleen, lung, and kidney)
showed no thrombus, infarction or abnormalities in gross appearance and H&E staining.
| Histology of healing response and endothelialization
The macroscopic examination showed that at 1 month, both occluder surfaces smoothly attached to adjacent tissue except at the edge and axis area; at 3 months, the tips of the axes at both occluder sides were not entirely covered by adjacent tissue; at 6 months, the right surface of the occluders were completely covered by tissue, while the left surface was not because of the longer locking tube at the axis area; at 12 months, both occluder sides were covered by autologous tissue; and at 18 and 24 months, the covering tissue layer was much thicker (Figure 3 ). In electron microscopy examination during follow-up, both device surfaces were comprehensively covered by endothelium starting at 
| Device degradation
In terms of occluder degradation post procedure, an obvious timedependent behavior was found in both gross anatomy and H&E staining. At 1 month, neither discs nor skeletons were degraded; at 3 months, the discs were less visible, but skeletons remained clearly visible; at 6 months, the discs were almost degraded, but the skeletons maintained their structural continuity. At the later stage of 6-12 months, the discs were completely degraded and replaced by the autogenous tissue, and the profile of skeletons became vague. After PLLA properties vary according to molecular conformation, 17 and current PLLA bioimplants can be fully absorbed over 2 years after implantation. 18 PLLA has good anti-tensile strength, 19 and in 2016, Xie et al 13 reported favorable 12-month efficacy and safety in swine of a PLLA skeleton and fabric-based device for ASD closure consisting of two discs and a waist for linkage. PDLLA is broadly used in resorbable membranes for bone regeneration engineering 20 and favors biomaterial-epithelial integration with appropriate surface proteomic signature technology, rendering it promising for use in medical devices. 21 The degradation process of the novel ASD occluder generally accorded with the material properties noted above. Although the PLLA skeleton was still partly undegraded after 2 years in vivo, the molecular weight showed a distinct decrease during the follow-up. And during the whole follow-up, only mild-to-moderate inflammatory response was observed, which might be explained as the healing response.
22,23
BioSTAR, is thus far the only biodegradable device approved for ASD closure, however, incomplete degradation and residual shunts and other complications limit its effectiveness. [9] [10] [11] Occluder devices with polydioxanone skeleton and PLLA discs introduced by Dai et al in 2010 with favorable short-term results in animal models 24 were later improved by Zhu et al using the same materials, and the 24-week follow-up seemed too short for the device to be completely absorbed. 25 Recently, a self-centering designed ASD occluder was proposed by Sigler et al. 26 With the poly (lactic-co-glycolic acid) monofilament as the main material and the follow-up period of 15 months, this device showed good biocompatibility. But designed for fluoroscopy-guided interventional therapy, the devices mentioned above inevitably need the metal marker which was visible under X-ray, and thus made incomplete degradation an unescapable result.
Differently, this novel device could be smoothly implanted in vivo with only ultrasound guidance, so it did not comprise any metal components, which would impede the complete degradation of the device. On the other hand, although without a self-centering design (such as a "waist"), this device was proved to be qualified of preventing shifting after implantation in the present study. As designed for ASD with narrow pathway to go through but larger range to be covered (such as multi-fenestrated ASD and patent foramen ovale), self-centering design would be encumbrance. And the narrow pathway could to some extent take place of the self-centering design, also, the tightened contact of the skeleton with the two discs clamps the defect's fringe to fix the device right on the ASD.
In this study, we used adult sheep to test the novel device for following reasons: (1) the size of their heart approximates that of human heart; (2) their coagulation and fibrinolytic systems are closer to that of humans; and (3) they tend to have a stable body size and weight during a long-term follow-up when compared with swine. 12, 27 We punctured and created the ASDs at the fossa ovalis areas because we could have a stable ASD size here compared with the septum secundum. 28 
FIGURE 4
Average molecular weight of the PLLA skeleton at different time points after implantation Although PLLA was reported to have qualified tensile strength and good biocompatibility, its low degradation velocity was quite a limitation. In this study, the resorption of the PLLA framework was still underway at the endpoint, and the cause of the late-stage inflammation response observed at 2 years after implantation was still uncertain. It might be explained as an accelerated healing response with following reasons: the response was mild and circumscribed and the rectal temperatures, blood test results, and electrocardiograms of the sheep were all within normal ranges.
Moreover, the endothelialization was already completed at 12-month point, and the molecular weight of the PLLA skeleton had already decreased to 9% of initial. And we speculated that with the completely degradation of the device, the inflammation response would subside concurrently. But to be more precisely, it needs to be identified with longer follow-up. And work would be done to the shorten the degradation time of the polymer framework without affecting the tensile strength and biocompatibility. Also, study in human has been underway based on the promising results of the present experimental study in sheep.
| CONCLUSIONS
The present study indicates that the use of a novel fully biodegradable occluder is feasible, efficacious, and safe for ASD interventional 
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